Melanotan-2 (MT-2) is Certified Aminos' research listing for a synthetic cyclic peptide analog of alpha-MSH that non-selectively activates multiple melanocortin receptors. It is a distinct molecule from afamelanotide (Scenesse), an FDA-approved drug for a specific rare disease. Peer-reviewed case reports have linked Melanotan II use to serious adverse events including acute kidney injury and atypical skin lesions. Available in 10mg for laboratory research use only.
HPLC certified
Independent analysis
Highest standard
Full traceability
Each order ships as a Melanotan-2 research peptide in a 10mg vial, manufactured for laboratory use only.
| Product Name | Melanotan-2 (MT-2, Melanotan II) |
|---|---|
| Mechanism | Non-selective agonist at melanocortin receptors MC1, MC3, and MC4 |
| CAS Number | 121062-08-6 -- a commonly published literature value; not independently confirmed via the chemical databases checked (ChEMBL has no entry under "Melanotan II") |
| Molecular Formula | C50H69N15O9 -- same sourcing caveat as above |
| Related Compound Distinction | Melanotan-2 is a separate molecule from afamelanotide (brand name Scenesse), an FDA-approved drug for erythropoietic protoporphyria from a different development history. Approval and safety data for afamelanotide do not apply to Melanotan-2 or to this listing |
| Documented Safety Signals | Peer-reviewed case reports describe serious adverse events associated with Melanotan II use, including acute kidney injury and atypical skin lesions -- see Research Focus below |
| Purity | Not independently verified -- no batch-specific COA is currently published |
| Identity | Not independently confirmed by mass spectrometry or an equivalent method |
| Available Size | 10mg |
| Intended Use | Laboratory research only (RUO) |
When your order arrives, match the lot number printed on the vial to the lot number on the COA before beginning any work. Until a batch-specific COA is published for this product, treat any purity or identity figure shown elsewhere on this listing as a supplier claim, not an independently verified result.
Melanotan II non-selectively activates three melanocortin receptors — here's what controlled trials and case reports actually show, not what badges imply.
Melanotan-1 shares its exact sequence with the FDA-approved drug Scenesse — here's what that does and doesn't mean for a research-use listing, and what MC1R research actually shows.
HCG and LH bind the exact same receptor — yet research shows they send measurably different signals once they do. Here's what's actually established about HCG's structure, mechanism, and the FDA's position on HCG weight-loss claims.
